hepatitis, and other STI in both men and women); 65% are in young adults aged 20 to 40 years. 1 In 2016, the Spectrum-STI estimation tool was developed to complement the human immunodeficiency virus (HIV) tool and estimate trends in adult prevalence and incidence of STIs at national level, using standard indicator data from routine STI surveillance and population-based surveys. The model is embedded in the Spectrum suite of health program planning tools, anchored on projections of national population sizes over time. [2] [3] [4] The Spectrum acquired immune deficiency syndrome (AIDS) Incidence Model is used by over 120 countries to estimate HIV/AIDS burden and associated need for treatment.
Morocco has used the Spectrum-HIV module to annually estimate trends in its HIV/AIDS burden and associated need for ART and prevention services since 2005. In 2016, Morocco was chosen to pilot the Spectrum STI module to inform strategic planning for its STI response, and strengthen its STI surveillance system. 5 This article collates Morocco's data on chlamydia and gonorrhea prevalence, UD case reports and UD etiologies. Importantly, it presents estimates of the adult prevalence and incidence of gonorrhea and chlamydia in Morocco over 1995 to 2015, using prevalence survey data. Estimated male gonorrhea and chlamydia case numbers were then broken down into numbers symptomatic and asymptomatic to estimate cases with UD, to estimate UD treatment coverage and reporting completeness. We interpret the estimated time trends in STI rates and treatment and reporting patterns in the context of Morocco's recent STI control history and program development and discuss implications for national surveillance and programming.
METHODS

Overview
The Spectrum-STI estimation tool (http://avenirhealth.org/ software-spectrum.php) was used to estimate and project the prevalence of gonorrhea and chlamydia in men and women in Morocco's adult population (15-49 years) , based on statistical fitting of data from prevalence surveys. 6 Incidence was derived from prevalence by applying assumed average durations of infection. The completeness of UD case reporting was evaluated, relative to the total national UD case load based on estimated gonorrhea and chlamydia incidence.
Data and assumptions used to generate the Morocco estimates were reviewed, discussed, and agreed at 2 technical workshops held in Morocco in May and September 2016. Participants in the workshop included representatives of the Ministry of Health, HIV/AIDS and Maternal and Child Health programs; the central reference laboratory and key partners supporting or implementing the national HIV/STI response.
Prevalence Estimation
For both STIs, prevalence data from 1985 to 2015 were identified. Inclusion criteria were:
• Study population considered representative of the general adult population. This included pregnant women, women at delivery, women attending family planning clinics, and adults in household surveys. Studies conducted among the following groups were excluded: patients seeking care for an STI or genital symptoms, women with abnormal Papanicolaou smears, women attending gynecology or sexual health clinics, men who have sex with men, commercial female sex workers (FSW), or blood donors.
• Study used an internationally recognized diagnostic test with adequate performance characteristics on urine, urethral, serum or cervicovaginal specimens.
Prevalence data from each study were adjusted for the sensitivity and specificity of diagnostic tests used [7] [8] [9] ; Supplemental Digital Content (SDC) 1, http://links.lww.com/OLQ/A179. To allow uncertainty analyses, any (test-adjusted) prevalence of zero was imputed to be 1 case divided by 100 times the sample size Supplemental Digital Content (SDC) 2, http://links.lww.com/OLQ/ A179. Studies conducted in exclusively rural or urban sites were converted into a national prevalence by applying a rural to urban ratio of 0.9 weighted by the urban/rural population ratios for Morocco, 10 as done in the World Health Organization (WHO)'s 2012 regional STI estimations. 7 Each prevalence data point was adjusted upward by 10% to account for the contribution of higherrisk populations. 7 The Spectrum-STI module provides the option of using data from other countries to supplement national data. In the current model application, these studies were given a weight of 10%. In addition, the WHO's 2012 regional prevalence estimates for women in the Eastern Mediterranean region were included and assigned a weight of 1%. Despite the small weights, these data additions may help alleviate the absence of data for Morocco for specific years and may account for regional trends not captured sufficiently in the Morocco data.
To allow a trend estimation including all eligible male and female data points combined, each male prevalence was converted into a corresponding female prevalence by applying a fixed maleto-female prevalence ratio, set at 0.86 for gonorrhea and 0.80 for chlamydia (as in the WHO 2012 global and regional estimations 7 ). The estimation was done for female prevalence; thereafter, the corresponding male prevalence at each year was generated by applying the same (time-constant) male-to-female prevalence ratios. National prevalence was estimated over time as a moving average through all adjusted data points, with the weights specified that reflect geographical relevance, with a 95% confidence interval (CI) derived by bootstrapping, using 10,000 replications that considered each study's sample size. 6 
Incidence Estimation
Incidence was derived from the prevalence trend estimates, assuming that the incidence hazard or density (among uninfected people) was constant in each of the consecutive intervals of length 1 year, for t starting from 1995. If the incidence hazard or density, i, and STI episode duration, D, are constant in an interval (t 0 , t 0 + 1), then for all t in that interval, the prevalence satisfies the equation:
where r = 1/D (Supplemental Digital Contents (SDC) 3, http:// links.lww.com/OLQ/A179 and 4, http://links.lww.com/OLQ/A179). We solved equation 1 for i piecewise every year, after setting t = t 0 + 1, for t 0 = 1995, 1996, … to obtain its time trend, and then calculated the corresponding incidence rate 'IR' per capita of national adult population, as: IR = i(1 − p), where p is the prevalence Supplemental Digital Content (SDC) 4, http://links.lww. com/OLQ/A179).
The 95% CIs on incidence bounds reflect both the uncertainty (estimated by bootstrap) in prevalence, and an additional uncertainty on the duration of infection, set at ±50%. 15 have documented increases in STI treatment, overall and for public clinics specifically. To reflect this, we assumed that the probability of an infected, symptomatic adult being adequately treated in 1995 was half (eg, in men, 21% for gonorrhea and 3.6% for chlamydia) of what it was in 2015 (in men, 42% for gonorrhea and 7.2% for chlamydia), and that this treatment coverage had increased linearly over time Supplemental Digital Content (SDC) 3, http://links.lww.com/ OLQ/A179. Based on treatment coverage estimated for each year, the average duration of gonorrhea and chlamydia episodes in each year was calculated, by weighting between the fraction treated and the fraction untreated Supplemental Digital Content (SDC) 3, http://links.lww.com/OLQ/A179. The year-specific treatmentweighted durations were then applied to derive annual incidence from annual prevalence.
STI Episode Durations
UD Reporting Completeness
National-level UD case reports over 1995 to 2015 collated by the national STI programme Supplemental Digital Content (SDC) 5, http://links.lww.com/OLQ/A179 were compared to Spectrum-estimated national UD case load, based on estimated gonorrhea and chlamydia incident cases. UD case load was generated by adjusting gonorrhea and chlamydia incidence estimates by the proportion of UD cases due to gonorrhea and chlamydia according to etiological studies Supplemental Digital Content (SDC) 6, http://links.lww.com/OLQ/A179, and proportions of male episodes that are symptomatic and treated Supplemental Digital Content (SDC) 3, http://links.lww.com/OLQ/A179.
The national UD case reports cover adult men over 15 years of age. To compare the model results with these case reports, we assumed the incidence rate in men 50 to 64 years was the same as in men 15 to 49 years.
Sensitivity Analysis
The sensitivity of results to key assumptions were assessed in univariate sensitivity analyses, focusing on prevalence, incidence, and UD reporting completeness at 2015.
RESULTS
Gonorrhea and Chlamydia Prevalence
Three surveys were identified in Morocco that met the study entry criteria. Two surveys, in 1999 and 2011 to 2012, provided data for gonorrhea and chlamydia prevalence, in both ANC and Family Planning women. Additionally, 1 study was included that measured chlamydia only, over 1994 to 1996, in ANC women and male blood donors (Supplemental Digital Content (SDC) 2, http://links.lww.com/OLQ/A179 Fig. 1 ).
No qualifying data for either gonorrhea or chlamydia were identified from Morocco's geographically bordering countries, but the group of national experts decided to include data from Egypt, considering its presumed similar demographic and sociobehavioral situation. One survey from Egypt, conducted among women attending ANC and family planning clinics in 1999 to 2000, was included for both STIs; additionally, for chlamydia, we included 6 data points from low-risk population surveys conducted over 1985 to 1994 Supplemental Digital Content (SDC) 2, http://links.lww.com/ OLQ/A179.
For gonorrhea in women, Spectrum estimated a stable prevalence around 0.6% over 1995 to 1999 followed by slight decline over 1999 to 2011. Corresponding gonorrhea prevalences for men were 0.53% (0.26-0.93%) at 2000 and 0.32% (0.12-0.87%) at 2015.
For chlamydia, Spectrum estimated a slight decline over 1995 to 2011 (the last year with survey data), and stable prevalence thereafter (Fig. 1) . Chlamydia prevalences were 4.7% (2.1-6.4%) in women and 4.1% (2.6-6.1%) in men in 2000, and 3.8% (2.1-6.4%) in women and 3.0% (1.7-5.1%) in men in 2015.
Over 1995 to 2015, gonorrhea and chlamydia prevalence had declined by 41% and 27%, respectively. Figure 2 shows the estimated historic trends in gonorrhea and chlamydia incidence. In 2015, the estimated prevalence estimates corresponded to 79,598 (23, 206 ) and 112,013 (28,700-307,433) new gonorrhea cases in women and men aged 15 to 49 years, respectively. Corresponding numbers for Figure 1 . Prevalence of gonorrhea and chlamydia in women 15-49 years in Morocco: Spectrum estimates and underlying data. Data are shown after adjustments for diagnostic test performance, urban/rural differences, and missing high-risk populations, as described in Methods. Regional estimates shown were those also used in the prevalence fitting, at a 1% weight relative to the national data points (see Methods), from WHO for the year 2012. 7 Gonorrhea's estimated case incidence rate declined from 1690 per 100,000 person-years in 1995 to 1290 per 100,000 in 2015 in men, and from 1370 to 870 per 100,000 in women ( Fig. 2A) . Over this period, estimated chlamydia incidence decreased from 4760 to 3610/1000,000 in men, and from 4250 to 3200 per 100,000 in women. Incidence rates were higher in men than in women, despite higher prevalence of both STIs in women-reflecting the longer duration of infection in women.
Gonorrhea and Chlamydia Incidence
UD Case Reporting Completeness, in 2015
Using the male gonorrhea incidence estimates for 2015 and the assumptions detailed in Supplemental Digital Content (SDC) 3, http://links.lww.com/OLQ/A179, the projected number of gonorrheal UD cases in 15-to 64-year-old men was 90,441, of whom 58,876 sought treatment (Table 2 ). For chlamydia, Spectrum estimated 43,579 symptomatic cases in men 15 to 64 years in 2015, of whom 28,327 were treated.
In 2015, a total of 71,999 UD cases were reported in adult men Supplemental Digital Content (SDC) 5, http://links. lww.com/OLQ/A179. If gonorrhea accounts for 63% of UD cases (, 15 Supplemental Digital Content (SDC) 6, http://links.lww. com/OLQ/A179) then the total estimated number of UD cases treated (from gonorrhea and other STIs) was 93,609, which suggests that the UD reporting completeness was 77% among cases treated in clinics.
Doing a corresponding analysis starting from the etiological fraction of chlamydia, with chlamydia accounting for 18% of clinical UD cases 15 then the total estimated number of UD cases treated would be 153,934, in which case the UD cases actually reported covered 46% of UD cases treated.
These estimates indicate that reporting completeness among clinically treated UD cases is quite high; however, the reported UD cases represented only 13% of all male gonorrhea and chlamydia cases in 2015, due to the large number of asymptomatic and untreated cases, especially of chlamydia (Fig. 3) .
Reporting Completeness, Treatment Coverage, and Case Incidence over 1995-2015 Figure 3 shows estimated time trends in incident cases in men. Comparing reported UD cases with estimated incident cases over 1995 to 2015, UD reporting completeness increased from 46% to 77% among treated cases when based on gonorrhea incidence estimates; or from 41% to 46% when based on chlamydia incidence estimates. The trends suggest a marked improvement in treatment coverage and reporting completeness around 1999 to 2002, coinciding with Morocco's implementation of the syndromic STI treatment approach in 2000. 16 The total number of new gonorrhea cases in men in 1995 and 2015 were similar, reflecting a slight decline in incidence rate balanced by population growth. Within this total, the numbers of asymptomatic and not treated cases, and of symptomatic treated but not reported cases, were stable over time; in contrast, the number of symptomatic, treated and reported cases increased over 3-fold (Fig. 3A) . For chlamydia, there was slight increase in the total cases over 1995 to 2015, reflecting population growth and a modest decline in incidence rate (Fig. 3B) , and the number of cases that were symptomatic, treated, and reported more than doubled.
Sensitivity Analysis
Changes to the assumptions used to estimate prevalence trends, in terms of the weights attached to data from neighboring countries, and to the annual dilution factor used in the movingaverage trend estimation, 17 had a greater effect on prevalence estimates for gonorrhea than for chlamydia ( Table 3 ). The implied UD reporting completeness changed in the opposite direction of changes in the prevalence and incidence estimate for gonorrhea (within a range of 59-91%). UD reporting completeness did not change much (range, 41-49%) when compared with estimated chlamydia rates under varying assumptions.
Gonorrhea prevalence was slightly sensitive to the weight given to data from Egypt, whose prevalence survey at 1999 to 2000 had measured higher prevalence than both Moroccan surveys. When excluding the Egypt data, gonorrhea prevalence at 2015 would be 0.27% instead of 0.32%; in this case national UD reporting completeness would have been 48% to 91%. Reporting completeness among UD cases treated in clinics shown, is the average of the reporting completeness estimates calculated relative to gonorrhea incidence, and the completeness relative to chlamydia incidence, as shown for year 2015 in Table 2 .
Assuming no incidence in men 15 to 64 years, or assuming lower proportions of UD cases to be treated, increased reporting completeness estimates (to 47-97%), whereas assuming a higher proportion of male chlamydia episodes to be symptomatic, 54% as in WHO's regional estimation, 7 instead of the default assumed 11% implied a much lower estimated reporting completeness (of 7%, instead of 46%) when evaluated relative to estimated chlamydial UD cases.
DISCUSSION
Trend estimations through Spectrum-STI model applied to prevalence survey data indicated prevalence declines in chlamydia and especially in gonorrhea over 1995 to 2015 in Morocco. Estimates are more certain (narrower 95% CIs) for chlamydia than for gonorrhea, as for chlamydia, there were more data points. For both STIs, the uncertainty in STI prevalence and incidence increased after 2012, because no national surveys were conducted post-2012. Chlamydia was estimated to be around 5-fold more prevalent than gonorrhea, in line with the 2012 WHO regional estimates, 7 although for both STIs, Morocco's estimated prevalence in 2012 was below the WHO's estimate for the Eastern Mediterranean region as a whole 7 (Fig. 1) . The estimated decreasing prevalence and incidence for gonorrhea is in keeping with data from women consulting with vaginal discharge and/or lower abdominal pain, where gonorrhea prevalence fell from 4.8% in 1996 in Agadir, Marrakech and Tanger 18,19 to 1.0% in 2007 in Agadir, Rabat/Salé, and Tanger. 20 In these study populations, in contrast, chlamydia did not decline, with 5.3% infected in 1996 and 5.6% in 2007. These declines are furthermore in line with Spectrum-STI prevalence trend estimates for adult syphilis, 6, 21 and the reported declines in HIV incidence (after a peak at 2002-2004) in Morocco. 5, [22] [23] [24] These trends coincide with expansion of the HIV/STI response and services in Morocco over the last 2 decades, including for FSW. 25 Commercial sex networks play the leading role in HIV transmission in Morocco 23, 26 and also probably drive gonorrhea and chlamydia transmission. Morocco is a pioneer in the Eastern Mediterranean region in adapting its HIV/ STI response to where needs are, and in implementing programs targeted at different at-risk populations. 25 Nongovernmental organizations with the support and collaboration of national authorities have scaled-up HIV counseling and testing services, with particular uptake by FSWs in the main cities since 2012, 27 as well as the free distribution of condoms. 28 About half of FSWs report condom use during last sex act across recent surveys, [22] [23] [24] [25] [26] an increase from year 2003, 28 highlighting the progress of HIV/ STI response since earlier years.
The declines in gonorrhea and chlamydia prevalence are likely attributable to a combination of factors associated with the expanded HIV/STI response: improved treatment coverage, improved reporting of cases treated, and a fall in sexual risk behaviours (eg, nonuse of condoms during commercial sex), possibly in part thanks to testing and counselling services for HIV.
Comparison of the actual number of reported UD cases in men and estimated incident cases suggests that treatment coverage of symptomatic gonorrhea and chlamydia cases may have doubled from 1995 to 2015 and reporting completeness may have improved from 41-46% to 46-77%.
The triangulation of comparative trends in both STIs and their determinants suggests there was a major improvement in clinical STI services around the year 2000. This concords with changes in national policy and data from Morocco's KAP studies, which suggest an improvement in treatment coverage since 2001. [12] [13] [14] [15] In 2000, Morocco adopted the syndromic treatment approach and standardized its protocols, 16 thereby facilitating better planning of drug and diagnostic needs and possibly improving patient access. More recent improvements may be linked to the introduction of obligatory health insurance in 2004, although officially STI treatment has been free in the public sector ever since 1995.
The estimates of reporting completeness seem to be consistent with Morocco's earlier independent estimate of reporting completeness, in the year 1999: in men and women combined, a total of 276,750 cases (of any STI) were notified, whereas for that year, 600,000 cases were estimated, 16, 29 implying a 46% reporting completeness. Our slightly higher UD reporting completeness estimate (56-70% in 1999) may reflect that, due to higher treatment coverage in men than in women, 30 reporting completeness will typically be higher for men than for women and men combined.
For 2015, the estimated 46% to 77% reporting completeness among treated UD cases would seem reasonable, given that since 2006 Morocco's Ministry of Health and its provincial offices actively chase health facilities in case of missing or late notification reports. However, this national-level completeness may have to be interpreted in light of possible UD overreporting by some health facilities in attempts to justify procurement of medications.
Limitations
The biggest challenge to model-based estimates are the quantity, representativeness and bias of data available. Notably, differences in prevalence between studies may reflect true trends or methodological sources of bias.
In addition, incidence estimates depend on treatment coverage and the assumed durations of-treated and untreatedinfection, for which there is a lack of empirical longitudinal data. Assumed proportions of episodes that become symptomatic were calibrated on earlier WHO estimates for the entire Eastern Mediterranean region, 7 not on Morocco-specific data. The proportion of symptomatic episodes that are treated was also taken from a regional-level WHO assumption, although the 65% was in line with data from Morocco's KAP studies (see Supplemental Digital Content (SDC) 3, http://links.lww.com/OLQ/A179).
The estimated reporting completeness also depended on UD etiology distributions. Three studies were identified in Morocco, but how representative they are is hard to tell because they were from selected sites and had small samples Supplemental Digital Content (SDC) 6, http://links.lww.com/OLQ/A179.
Implications for Surveillance, and Programmatic Response
There is a lack of recent population based prevalence data for both chlamydia and gonorrhea in women and no good data in men. To improve trend estimation, Morocco would benefit from one or more population-based prevalence surveys that collect data on multiple STIs in men and women in both urban and rural areas. Securing funding for such surveys is challenging given broader health and surveillance prioritizations. Screening and treatment programs for chlamydia in adolescents, as recommended in the WHO's global STI strategy 2016 to 2021 31 may yield useful data, but is as yet not implemented in Morocco.
Stable annual UD case numbers, reflecting improving treatment coverage and reasonably good UD reporting completeness, obscure recent declines in rates of nonulcerative STIs in Morocco, which are encouraging and for which the program can take credit. Also, although gonorrhea is the predominant cause of UD cases seen in clinics, at population level the prevalence, incidence and case numbers are much higher for chlamydia, and chlamydia has declined less than gonorrhea. Still large numbers of chlamydia cases are not being treated, firstly because many chlamydia infections in both men and women do not cause symptoms, and second, because over half of symptomatic chlamydia-infected adults (in our best estimates) do not seek or access treatment.
As other countries, Morocco has seen resistance of Neisseria gonorrhoeae against two of the common first-line drugs, ciprofloxacin and tetracycline, rising to high levels between 2001 14 and 2009. 15 It is hoped, but remains to be confirmed by ongoing surveillance of gonorrhea rates (in conjunction with drug resistance surveillance and etiology monitoring), that the switch in first-line treatment (from ciprofloxacin to ceftriaxone) will contribute to maintaining the recent gonorrhea prevalence decline.
CONCLUSIONS
Model-based estimations based on prevalence surveys suggests that gonorrhea and chlamydia have declined in Morocco, due to improved treatment coverage and a reduction in risk behaviours. These findings highlight the pioneering role of Morocco within the Eastern Mediterranean region in changing policies and rolling out effective national HIV/STI programs. These results, and the wide CIs around many of the estimates, argue for improved data input though periodic prevalence surveys, within and possibly beyond key populations. Our findings also highlight a largely hidden burden of untreated chlamydia, that merits intensification of control efforts beyond routine clinical services. There is a need for increased screening in primary care settings, among key populations, within antenatal care, and youth health care settings, such as school-based clinics. New diagnostic and delivery approaches and affordable rapid point-of-care tests 31 should facilitate clinicbased and non-clinic-based screening expansion, thus improving treatment coverage and surveillance and reducing disease burden.
